An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations

Inclusion Criteria:

- Pediatric patients, 12 to 17 years of age inclusive

- Histologically confirmed surgically incurable and unresectable Stage IIIC or Stage IV
(AJCC) melanoma

- Positive BRAF mutation result (Cobas 4800 BRAF V600 Mutation Test)

- Measurable disease according to RECIST criteria

- Performance status: Karnofsky (for patients >/= 16 years of age) or Lansky (for
patients < 16 years of age) score of >/= 60

- Adequate bone marrow, liver and renal function

- Patients must have fully recovered from the acute toxic effects of all prior therapy
prior to first administration of study drug

Exclusion Criteria:

- Active or untreated central nervous system (CNS) lesions

- History of or known spinal cord compression or carcinomatous meningitis

- Anticipated or ongoing administration of anti-cancer therapies other than those
administered in this study

- Previous malignancy within the past 5 years except for basal or squamous cell
carcinoma of the skin, melanoma in-situ, and carcinoma in-situ of the cervix

- Previous treatment with selective/specific BRAF or MEK inhibitor (previous treatment
with sorafenib is allowed)

- Any previous treatment with study drug (RO5185426) or participation in a clinical
trial that includes RO5185426

- Pregnant or lactating females

- Known HIV positivity or AIDS-related illness, active hepatitis B virus, or active
hepatitis C virus